Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27004161)
Watch
English
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
review article
1 reference
stated in
Europe PubMed Central
title
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
(English)
0 references
author name string
Peter B. Alexander
series ordinal
1
1 reference
stated in
Crossref
Xiao-Fan Wang
series ordinal
2
1 reference
stated in
Crossref
language of work or name
English
1 reference
stated in
PubMed
publication date
June 2015
1 reference
stated in
PubMed
published in
Frontiers of medicine
1 reference
stated in
PubMed
volume
9
1 reference
stated in
PubMed
issue
2
1 reference
stated in
PubMed
page(s)
134-8
1 reference
stated in
PubMed
exact match
https://scigraph.springernature.com/pub.10.1007/s11684-015-0396-9
0 references
cites work
Cell signaling by receptor tyrosine kinases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
21 March 2017
Cancer drug resistance: an evolving paradigm
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
7 April 2017
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
7 April 2017
Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Drug resistance to targeted therapies: déjà vu all over again
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
The quest to overcome resistance to EGFR-targeted therapies in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
RON confers lapatinib resistance in HER2-positive breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Noncovalent wild-type-sparing inhibitors of EGFR T790M
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Oncogene addiction
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Targeted cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535791
retrieved
28 September 2017
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1007%2FS11684-015-0396-9
retrieved
21 January 2018
EGF promotes mammalian cell growth by suppressing cellular senescence
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1007%2FS11684-015-0396-9
retrieved
21 January 2018
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1007%2FS11684-015-0396-9
retrieved
21 January 2018
Identifiers
DOI
10.1007/S11684-015-0396-9
0 references
Dimensions Publication ID
1010342210
0 references
PMCID
4535791
1 reference
stated in
PubMed
PubMed ID
25957263
1 reference
stated in
PubMed
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
